Navamedic ASA Achieves Final Approvals for Flexilev in Nordic Markets
Navamedic ASA is thrilled to announce that it has successfully received essential approvals for the packaging materials of its innovative Flexilev in national languages across the Nordic countries, including Norway, Sweden, and Denmark. This achievement follows a previous announcement regarding progress for the Finnish market. The collaboration with Orion Corporation, which holds the licensing rights for Finland and the rest of the EU, has also confirmed final approvals for this market.
Excitement Surrounds the Launch of Flexilev
Kathrine Gamborg Andreassen, the Chief Executive Officer of Navamedic, expressed her excitement about this significant milestone: "We are excited to have received the last approvals, paving the way for our go-to-market launch in the Nordic region." This statement highlights the company's eagerness to provide solutions tailored to the unique needs of Parkinson's patients.
Innovative Solution for Parkinson’s Patients
Flexilev in OraFID provides a groundbreaking approach to treating Parkinson's disease by ensuring precise and personalized medication tailored to each patient's unique requirements. For patients relying on medications with narrow therapeutic windows, Flexilev can significantly improve treatment outcomes through hyper-fractionation. This involves administering smaller, more frequent doses that optimize efficacy and reduce potential side effects.
The OraFID system is a unique medical device that stands out for its fully mechanical design, allowing users to dispense precise quantities of minitablets with just a simple turn of the hand. This innovation is set to enhance the treatment experience for countless patients across the Nordic region.
Anticipated Market Launch
The launch of Flexilev is eagerly anticipated in October 2025. As the company prepares for this important release, various strategic initiatives are being undertaken to ensure a smooth entry into the competitive pharmaceutical landscape.
About Navamedic ASA
Navamedic ASA is a leading Nordic pharmaceutical company dedicated to improving the quality of life for people through the delivery of high-quality prescription, consumer health, and hospital products. With a robust portfolio specifically designed to address contemporary public health challenges such as obesity, Parkinson's disease, and gastro-related issues, Navamedic empowers individuals to lead healthier lives.
The company prides itself on its commitment to understanding the diverse needs of the markets it serves. This local insight enables Navamedic to successfully navigate market access and become a preferred partner for international companies looking to expand in the Nordics and Benelux regions.
Company Contact Information
For further inquiries, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Lars Hjarrand, CFO, Navamedic
Mobile: +47 951 78 680
Mobile: +47 917 62 842
Frequently Asked Questions
1. What is Flexilev?
Flexilev is a medication designed for Parkinson's patients, aiding in precise and personalized treatment regimens through the OraFID system.
2. When will Flexilev be available in Nordic markets?
The launch is expected to take place in October 2025, following the recent approvals.
3. Who is behind the Flexilev product?
Flexilev is developed by Navamedic ASA, in partnership with Orion Corporation for certain EU markets.
4. What makes OraFID unique?
OraFID is a patented mechanical device that allows for the precise dosing of minitablets with a simple twist.
5. How does Navamedic ensure quality in its products?
Navamedic is committed to high-quality standards in all its offerings, focusing on meeting public health needs and maintaining rigorous quality control.
